The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1303
PPI Interactions with Clopidogrel
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Clopidogrel (Plavix), which prevents arterial thrombosis by inhibiting platelet activation, is commonly prescribed (usually with aspirin) for months after acute coronary syndromes and stent implantation.1 It may also, however, increase the risk of bleeding.2 Therefore, a proton pump inhibitor (PPI) such as omeprazole (Prilosec, and others) is often given concurrently to decrease the risk of gastrointestinal (GI) bleeding.2 Some reports have suggested that omeprazole may interfere with the antiplatelet effect of clopidogrel.

PHARMACOKINETICS — Clopidogrel is a prodrug that is activated by CYP450 enzymes in the liver, principally (it is thought) by CYP2C19. Omeprazole is a strong inhibitor of CYP2C19, but all PPIs may inhibit CYP2C19 to some extent.3 Patients who are carriers of CYP2C19 loss-of-function polymorphisms ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: PPI Interactions with Clopidogrel
Article code: 1303b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian